Sign in →

Test Code MISCLM PNH, PI-Linked Antigen, Blood

Additional Codes

 

MAYO Test ID

PLINK

EPIC Test ID

LAB2608

 

Reporting Name

PNH, PI-Linked AG, B

Useful For

Screening for and confirming the diagnosis of paroxysmal nocturnal hemoglobinuria (PNH)

 

Monitoring patients with PNH

Additional Tests

Test ID Reporting Name Available Separately Always Performed
FCIMS Flow Cytometry Interp, 9-15 Markers No, (Bill Only) Yes

Method Name

Immunophenotyping

Performing Laboratory

Mayo Medical Laboratories in Rochester

Specimen Type

Whole blood


Specimen Required


Specimen must arrive within 72 hours of draw.

 

Container/Tube:

Preferred: 2.6-mL Yellow top (ACD)

Acceptable: 7-mL ACD or lavender top (EDTA)

Specimen Volume: 2.6 mL

Collection Instructions: Do not transfer blood to other containers.


Specimen Minimum Volume

1 mL

Specimen Stability Information

Specimen Type Temperature Time
Whole blood Ambient (preferred) 72 hours
  Refrigerated  72 hours

Reject Due To

Hemolysis

Mild OK; Gross reject

Lipemia

NA

Icterus

NA

Other

NA

Reference Values

An interpretive report will be provided. 

 

RED BLOOD CELLS:

PNH RBC-Partial Antigen loss: 0.00-0.99%

PNH RBC-Complete Antigen loss: 0.00-0.01%

PNH Granulocytes: 0.00-0.01%

PNH Monocytes: 0.00-0.05%

Day(s) and Time(s) Performed

Specimens are processed Monday through Sunday and reported Monday through Friday.

CPT Code Information

88184-Flow cytometry, RBC x 1

88184-Flow cytometry, WBC x 1

88185-Flow cytometry, additional marker (each), RBC x 1

88185-Flow cytometry, additional marker (each), WBC x 6

88188-Flow Cytometry Interpretation, 9-15 Markers x 1

LOINC Code Information

Test ID Test Order Name Order LOINC Value
PLINK PNH, PI-Linked AG, B In Process

 

Result ID Test Result Name Result LOINC Value
CK079 Interpretation 69052-9
CK080 PNH RBC-Partial Ag Loss In Process
CK081 PNH RBC-Complete Ag Loss In Process
CK082 PNH Granulocytes In Process
CK083 PNH Monocytes In Process

Analytic Time

1 day

Test Classification

This test was developed using an analyte specific reagent. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.